Experiences with Nausea and Vomiting During Pregnancy in Turkish Women Based on Roy Adaptation Model: A Content Analysis

Gözde Gökçe İsbir,Samiye Mete 한국간호과학회 2013 Asian Nursing Research Vol.7 No.4

Purpose: This qualitative study aimed to explore how Turkish women experience nausea and vomiting in pregnancy based on the Roy Adaptation Model. Methods: To collect data, in-depth interviews were undertaken with 35 pregnant women who had nausea and vomiting. The sample of the study included pregnant women who were in their first 12 weeks of gestation, did not have medical problems and had nausea, retching and/or vomiting for at least the last 3 days. Data were collected in semi-structured interview form based on the Roy Adaptation Model and with a background data sheet. Data were analyzed using direct content analysis. Results: Data were classified into four adaptive modes according to the Roy Adaptation Model. The behaviors in the physiological mode were nausea, vomiting, fatigue, changes in sleep patterns, inadequate nutrition, inguinal pain, burning sensation and irritation in the throat, ketosis, and urinary incontinence. The behaviors in the self-concept mode were feeling weak, crying, inadequate self-care, changes in sexual intercourse, and social isolation. The behaviors in the role function mode were being unable to fulfill the responsibilities at home and work. The behaviors in the interdependence mode were dissatisfaction with relationships. Conclusion: The study findings help nursing staff detect the stimuli and the behaviors of pregnant women with nausea and vomiting. Further research may evaluate the impact of a counseling program prepared under the guidance of a nursing model on nausea and vomiting in pregnancy. Purpose: This qualitative study aimed to explore how Turkish women experience nausea and vomiting in pregnancy based on the Roy Adaptation Model. Methods: To collect data, in-depth interviews were undertaken with 35 pregnant women who had nausea and vomiting. The sample of the study included pregnant women who were in their first 12 weeks of gestation, did not have medical problems and had nausea, retching and/or vomiting for at least the last 3 days. Data were collected in semi-structured interview form based on the Roy Adaptation Model and with a background data sheet. Data were analyzed using direct content analysis. Results: Data were classified into four adaptive modes according to the Roy Adaptation Model. The behaviors in the physiological mode were nausea, vomiting, fatigue, changes in sleep patterns, inadequate nutrition, inguinal pain, burning sensation and irritation in the throat, ketosis, and urinary incontinence. The behaviors in the self-concept mode were feeling weak, crying, inadequate self-care, changes in sexual intercourse, and social isolation. The behaviors in the role function mode were being unable to fulfill the responsibilities at home and work. The behaviors in the interdependence mode were dissatisfaction with relationships. Conclusion: The study findings help nursing staff detect the stimuli and the behaviors of pregnant women with nausea and vomiting. Further research may evaluate the impact of a counseling program prepared under the guidance of a nursing model on nausea and vomiting in pregnancy.

기능성 구역과 구토의 진단과 치료

신정은 ( Jeong Eun Shin ) 대한내과학회 2012 대한내과학회지 Vol.82 No.5

Functional nausea and vomiting is a broad term used to be described a subset of individuals who have chronic nausea and vomiting without apparent cause, despite extensive evaluation. According to the Rome III criteria, functional nausea and vomiting can be subdivided into three separate entities: chronic idiopathic nausea, functional vomiting and cyclic vomiting syndrome. Although no specific test can diagnose these diseases, the diagnostic approach requires excellent history taking combined with judicious diagnostic testing to exclude some organic cause of chronic nausea and vomiting. These conditions are probably not psychogenic in origin. Treatment remains empirical for all patients with functional nausea and vomiting. Reassurance and supportive physician-patient relationship, along with use of low-dose tricyclic antidepressants, can be beneficial in caring for patients with chronic idiopathic nausea and functional vomiting. The cornerstones of management for patients with cyclic vomiting syndrome are identifying and avoidance of triggering factors, treatment with prophylactic antimigraine agents, 5-HT3 antagonists, benzodiazepines and 5-HT1 agonists (sumatriptan), with supportive therapy. (Korean J Med 2012;82:543-548)

Cyclic Vomiting Syndrome Developed after Stroke

Kwang Lae Lee,Jung In Shin 대한재활의학회 2012 Annals of Rehabilitation Medicine Vol.36 No.1

Cyclic vomiting syndrome is characterized by recurrent episodes of stereotyped vomiting separated by regular symptom-free periods. We describe a case of cyclic vomiting syndrome developed after stroke, which has not been reported to date. A 69-year-old woman experienced recurrent vomiting following left cerebral infarct. Th e patient’s vomiting pattern was consistent with cyclic vomiting syndrome, and the diagnosis of cyclic vomiting syndrome was established by exclusion of other known disorders which could have resulted in vomiting. She was treated with imipramine hydrochloride and her symptom was well controlled.

전이성 뇌종양 환자에게 발생한 오심(惡心), 구토(嘔吐)에 대해 가미복령반하탕으로 호전된 치험 1례

정종수,박재우,윤성우,Jeong, Jong-Soo,Park, Jae-Woo,Yoon, Seong-Woo 대한한방내과학회 2007 大韓韓方內科學會誌 Vol.28 No.4

In cancer patients showing nausea and vomiting, a number of factors can be considered as the cause including brain tumor, electrolyte imbalance, gastrointestinal diseases or types of chemotherapy agents and dose of the drugs. Though nausea and vomiting can be minimized through the use of various anti-emetic drugs, many people still suffer from severe nausea and vomiting with poor quality of life compared with patients who do not show significant nausea and vomiting. In this report, we introduce a case of a cancer patient who suffered from severe nausea and vomiting. The patient was female and 59 years old with NSCLC (non small cell lung cancer) with metastatic brain tumor. Though western conventional medical treatment was used to reduce the symptoms, persistent nausea and vomiting were noted during the admission period. Herbal decoction Gamibokryungbanha-tang was used for nausea and vomiting which were uncontrolled under conventional western medicine; the patient showed remarkable improvement in terms of frequency and severity of nausea and vomiting. Further study will be needed in order to determine the long-term effectiveness of oriental medical treatment on cancer patient with nausea and vomiting.

Nausea and Vomiting after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis

Wang, Shi-Ying,Zhu, Wen-Hao,Vargulick, Sonya,Lin, Sam Bill,Meng, Zhi-Qiang Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.10

Background: Nausea and vomiting after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) are common in clinical practice, but few studies have reported the incidence and risk factors of such events. Objective: The purpose of this study was to analyze the incidence and risk factors of nausea and vomiting after TACE for HCC. Methods: This study was a single-center retrospective analysis of a prospectively maintained database. Between May 2010 and October 2012, 150 patients with HCC were analyzed for incidence and preprocedural risk factors. Results: The incidence of postembolization nausea and vomiting was 38.8% and 20.9%, respectively, in patients with HCC. Patients who developed nausea had lower levels (<100 IU/L) of serum alkaline phosphatase (ALP) compared to those without nausea ($123.04{\pm}69.38$ vs. $167.41{\pm}138.95$, respectively, p=0.044). Female gender correlated to a higher incidence of nausea as well (p=0.024). Patients who developed vomiting, compared to those who did not, also had lower levels (<100 IU/L) of serum ALP ($112.52{\pm}62.63$ vs. $160.10{\pm}127.80$, respectively, p=0.010), and serum alanine transferase (ALT) ($35.61{\pm}22.87$ vs. $4.97{\pm}29.62$, respectively, p=0.045). There were no statistical significances in the incidences of nausea and vomiting between male patients over 50 years old and female patients who have entered menopause (p=0.051 and p=0.409, respectively). Multivariate analysis by logistic regression analysis demonstrated that female gender and ALP>100 IU/L were the most independent predictive factors of postembolization nausea (odds ratio (OR): 3.271, 95% CI: 1.176-9.103, p=0.023 and OR: 0.447, 95% CI: 0.216-0.927, p=0.030, respectively). ALP>100 IU/L was also the most independent predictive risk factor of postembolization vomiting (OR: 0.389, 95% CI: 0.159-0.952, p=0.039). Conclusions: Postembolizaiton nausea and vomiting are common in patients with HCC. Recognition of the risk factors presented above before TACE is important for early detection and proper management of postembolization nausea and vomiting. Nevertheless, future studies are required.

Psychiatric Co-morbidity and Efficacy of Mirtazapine Treatment in Young Subjects With Chronic or Cyclic Vomiting Syndromes: A Case Series

( Murat Coskun ),( Behiye Alyanak ) 대한소화기기능성질환·운동학회(구 대한소화관운동학회) 2011 Journal of Neurogastroenterology and Motility (JNM Vol.17 No.3

The aim of this case report was to evaluate the psychiatric co-morbidity and efficacy of mirtazapine treatment in young subjects with chronic or cyclic vomiting syndromes. This is a case series of 8 young subjects (age range of 6-16 years, 11.12 ± 3.52 years) who were referred or consulted to child psychiatry department. They were referred or consulted by pediatric gastroenterology or surgery departments for the presence of non-remitting and medically unexplained vomiting. They were investigated for co-morbid psychiatric disorders using a structured psychiatric interview. An open trial of mirtazapine was conducted for the treatment and/or prevention of vomiting. Primary outcome measure was Clinical Global Impression-Improvement scale. Subjects were diagnosed with chronic (n = 5) or cyclic (n = 3) vomiting syndromes. Duration of vomiting ranged from 6 months to 10 years (3.5 ± 3.2 years). All subjects received multiple psychiatric diagnoses with anxiety disorders being the most frequent. Maximum mirtazapine dosage was 7.5-30 mg/day (16.00 ± 6.16 mg/day). Three subjects showed complete remission and 5 subjects showed much to very much improvement in vomiting. Most frequent side effects were increased appetite, weight gain and sedation. Young subjects with chronic or cyclic vomiting may frequently suffer anxiety and/or depressive symptoms or disorders. Mirtazapine could be an effective treatment option for the treatment of vomiting and co-morbid anxiety or depressive disorders in these subjects. More systematic research are needed on this topic.

내관지압이 슬관절 전치환술 받은 노인 환자의 오심, 구토 및 통증에 미치는 효과

유제복 ( Je Bog Yoo ),장희정 ( Hee Jung Jang ),나은희 ( Eun Hee Na ),김선영 ( Sun Young Kim ),신동수 ( Dong Soo Shin ) 경희대학교 동서의학연구소 2011 동서간호학연구지 Vol.17 No.2

지압은 수직압, 지속압, 조화압으로 경혈을 찾은 다음 치료하는 사람의 체중을 실어서 위에서 아래로 누르는 방법으로 어깨에 불필요한 힘을 뺀 상태에서 자연스럽게 상체의 체중을 손가락에 집중을 시켜 수직으로 경혈을 보통 3-4초 정도 지속적으로 눌러 주는것을 말한다(East-west nursing research institute, 2000; Kim, 1999). 내관지압의 오심· 구토 경감 효과를 검증한 연구를 살펴보면, Alsaid 등(1997)이 수술 후 오심· 구토 감소에 효과가 있다고 보고하였고, Ming 등(2002)은 기능적 내시경 부비동 수술에 지압이 효과가 있다고 하였으며, Apfel 등(1999)은 항암화학요법을 받는 유방암 환자에게 지압이 오심과 구토에 유의한 차이가 있다고 보고하였다. Kim. 2003). Kim (2003)의 연구결과 내관지압이 항암화학요법을 받는 폐암 환자의 오심· 구토에 미치는 영향을 연구한 결과, 실험군에서 제2일과 3일에 오심 정도를 감소시키는 효과를 검증한 바 있다. 수술 환자의 자가 통증 조절기 사용은 최근 널리 적용되고 있는 통증완화를 위한 방법으로 자가 통증 조절기는 통증 완화를 위한 치료 효과는 높지만 오심· 구토는 대부분의 수술 후 자가 통증 조절기를 사용하는 환자들이 경험하는 심각한 불편감으로, 자가 통증조절기(PCA) 사용을 중단하게 되는 원인이 되기도 한다(Lee, 2006). 수술 후 오심, 구토는 통증보다 더욱 힘든 것으로 보고되고 있어, 이를 경감시켜 주기 위한 다양한 간호중재 전략의 개발이 요구된다Song & Shin, 1988). 본 연구는 슬관절 수술 환자의 자가 통증 조절기 사용 후 오심· 구토의 완화를 위해 내관지압을 적용하여 그 효과를 검증함으로써 비 침습적이고 독자적인 간호중재로서 발전시키기 위해 시도되었다. 본 연구 결과에서 내관지압 제공 후 24시간에 구토영역과 오심·구토 전체 영역에서 유의한 차이가 있었는데, 이는 Lee (2008)의 중이수술 대상자에게 손목밴드 내관지압을 적용한 결과 마취 종료후 24시간에 오심· 구토의 전체영역에서 유의한 차이가 나타났다는 결과와 일치하였다. 그러나 본 연구에서는 오심 영역은 유의미한 차이를 나타내지 못하여 Kim (2003)의 연구에서 항암화학요법주기 제2일 오심불편감이 실험군과 대조군 간에 통계적으로 유의한 차이를 보였다는 결과와 일치하지 않는 결과를 나타내었다. 이는 대상자의 차이에 의한 것으로 수술 환자와 항암요법대상자의 차이에서 비롯된 것으로 본다. Shin (2002)의 연구에서는 지압교육실험군에서 항암화학요법제투여 2일, 3일, 4일, 5일째 오심· 구토 정도가 유의미하게 감소하였다. 본 연구에서는 내관지압 제공 후 12시간에서 유의미하게 구토영역에서 감소를 나타내기 시작하였다. 이는 대상자가 다르기 때문으로 판단되며 항암요법을 실시하고 있는 대상자보다 고관절치환술 후자가통증조절기를 보유하고 있는 대상자의 오심· 구토 정도가 상대적으로 항암 환자보다 낮은 정도이기 때문으로 본다. Lee (2002)의 연구결과 오심 정도는 제3일째는 유의미한 차이가 있었으나 구토정 도에서는 유의미한 차이를 나타내지 않았다. 본 연구결과와는 차이를 나타내었다. 역시 항암요법을 받는 난소암 환자가 대상자이기 때문에 대상자의 차이로 인한 결과라고 본다. 따라서 앞으로 연구 시에는 동일대상자에 대한 반복연구가 필요함을 시사할 뿐 아니라 최초 효과발현 시기에 대해 다양한 대상자별 반복연구가 필요함을 알 수 있었다. 본 연구의 결과에서 내관지압 제공 후 24시간 시점에서 두 군 간의 오심· 구토 전체 점수는 유의미하게 낮았고 특히 구토 횟수, 구토불편감, 구토 양은 통계적으로 낮아 유의한 차이가 있었다. 그러나 Lee (2008)의 연구에서는 마취종료 후 24시간에 오심· 구토 전체 점수에서 유의미하게 차이가 났다는 결과와는 일치하였으나 세부 하위영역에서 유의미한 영역은 차이가 있다. 즉, Lee (2008)는 특히 오심에서 유의미한 차이를 나타내어 본 연구결과와 일치하지는 않았다. 이는 대상자의 수술의 심각성 정도에 따라 차이를 나타낸 것으로 보인다. Shin (2002)의 연구에서 항암화학요법을 받은 위암 환자에게 내관지압이 하위영역 구토 횟수 감소에 유의한 효과를 나타냈다는 결과와는 일치하였으며 Kim 등(2007)의 연구와도 일치하였다. 이는 지압 제공 후 12시간보다는 24시간에 효과가 큰 것은 시간이 지남에 따라 지압의 효과가 축적되어 나타나는 것이라 본다. Kwon(2011)의 결과 갑상선절제술 환자에게 손목밴드를 이용한 내관지압을 적용하였을 때 시간이 경과함에 따라 오심· 구토 점수가 감소하였다는 결과가 있었고 Kim 등(2010)의 결과에서는 시간에 따라 오심감소가 유의미하게 있었으므로 앞으로도 시간이 경과함에 따라오심· 구토의 감소효과를 계속해서 연구할 필요가 있다. Aidah 등(2002)의 연구결과 24-48시간에 구토의 부작용이 가장 심하게 나타난다는 연구결과가 있었는데 이때 지압을 통해 구토영역이 유의미하게 낮은 점수를 나타낸 것은 대조군은 구토의 부작용이 지속되지만 실험군은 지압의 효과로 구토의 부작용을 최소화하였기 때문이라 볼 수 있다. 그래서 본 연구의 실험군에서도 24시간에 가장 구토영역의 유의미하게 낮은 점수를 나타낸 것으로 본다. 본 연구결과는 24시간 시점에서 집중적으로 오심· 구토를 중재할 수 있는 간호 중재의 요구도가 있다는 것을 나타내는 증거라고 본다. 그러므로 앞으로는 내관(P6)지압을 24시간 이후 48시간에도 계속 적용한 후 오심· 구토 정도를 확인하는 반복 연구가 필요하다. 내관지압의 통증감소효과에 대한 가설을 세웠으나 본 연구결과 통증에는 효과가 나타나지 않았음을 보였다. 지압이 통증 감소에 영향을 미친다는 연구결과와 일치하지 않는 것을 보였다. Ju (2010)의 연구결과 경혈지압마사지가 요통 환자의 통증감소에 효과적이었다고 보고하였으나 이는 8주간의 장시간을 두고 효과를 검증한 것이었다. Shin (2004)은 자궁 적출술 환자의 통증 자가조절교육과 함께 내관지압을 실시한 실험군에서 통증감소효과가 있었다고 보고한 것과도 일치하지 않는 결과를 나타내었다. 이는 본 연구에서 이미 대상자 스스로 통증치료를 위해 PCEA를 사용하고 있으므로 통증에 대해서는 스스로 조절을 하는 부분이 더 영향을 미쳤을 것으로 본다. 그러나 앞으로의 연구에서는 PCEA를 착용하고 있으므로 이를 통한 통증약물 사용량을 함께 측정함으로써 통증 정도를 좀 더 정확하고 광범위하게 측정하여 통증 정도의 효과를 검증하는 것이 필요하다고 본다. 이상에서 논의한 바와 같이 본 연구는 수술 후 자가 통증 조절기사용 환자의 오심 및 구토, 통증 완화에 지압을 이용한 간호중재가 부분적으로 오심· 구토 감소에 효과를 나타낸다는 것을 검증하였으므로 임상에서 내관(P6)지압을 간호중재의 하나로서 적극 활용할 것을 제안한다. Purpose: Patient-controlled epidural analgesia (PCEA) is an effective method for controlling post surgical pain. However, it is associated with adverse drug reactions such as nausea and vomiting. In this, study we tested the effects of Nei-Guan (P6) acupressure on PCEA-associated nausea, vomiting, and pain in geriatric patients after total knee replacement arthroplasty (TKRA). Methods: Ninety-nine patients who had TKRA for the first time were randomly assigned to either, experiment group (n=50) or control groups (n=49). All patients received PCEA immediately after surgery, but acupressure on Nei-Guan (P6) point was applied to experiment group only. Ten minutes of finger acupressure on Nei-Guan (P6) acupressure point was applied twice with 15 minute-interval in the experiment group. The incidence of nausea, vomiting, and retching as well as pain intensity were assessed at 12 and 24 hours after surgery. Nausea, and vomiting were assessed by Index of Nausea, Vomiting and Retching (INVR) questionnaire. Pain intensity was measured with frequency of analgesics. Results: Vomiting both was significantly different between two groups at 12 hours (t=-2.18, p=0.03) and 24 hours (t=-2.64, p=0.01) after surgery. Total scores of nausea, vomiting and retching in experimental group was significantly lower than control group 24hours after surgery (t=- 2.18, p=0.03). However, pain was not different between two groups. Conclusion: Nei-Guan (P6) acupressure may be considered as an effective nursing intervention to decrease PCEA-associated nausea and vomiting in older patients after TKRA.

주기성 구토 증후군 환아에서 보인 F - 18 FDG PET 에서의 뇌 포도당 대사 소견

김유경(Yu Kyeong Kim),이동수(Dong Soo Lee),강은주(Eun Joo Kang),서정기(Jeong Kee Seo),여정석(Jeong Seok Yeo),정준기(June Key Chung),이명철(Myung Chul Lee) 대한핵의학회 2001 핵의학 분자영상 Vol.35 No.3

Cyclic Vomiting Syndrome (CVS) is characterized by recurrent, periodic, self-limiting vomiting. However, its pathogenesis is not yet established. We investigated the changes of the cerebral glucose metabolism using F-18 FDG during the vomiting attack and symptom free period in two children with CVS. FDG PET study showed the markedly increased metabolism in both temporal lobes and also in the medulla and cerebellum during the vomiting period. Also, FDG PET showed the decreased metabolism in the parieto-occipital and occipital areas during the vomiting period. The area with decreased metabolism seemed to be related with the region showing abnormalities in EEG and perfusion SPECT studies. We expect that what we observed would be a helpful finding in clarifying the pathogenesis of the CVS. (Korean J Nucl Med 200135:198-204)

Thyrotoxic Vomiting: A Case Report and Possible Mechanisms

( Yong Sung Kim ),( So Yeon Shim ),( Han Seung Ryu ),( Hyo Jung Oh ) 대한소화관운동학회 2010 Journal of Neurogastroenterology and Motility (JNM Vol.16 No.4

The symptoms related to gastrointestinal (GI) tract are sometimes chief complaints in patients with endocrine disease. Thyrotoxicosis is a rare, but notable cause for unexplained and repeated vomiting. Here, we report an adolescent patient with thyrotoxicosis who was initially presented with repeated vomiting and epigastric pain. A 13-year-old female was referred to a GI outpatient department for evaluation of vomiting and abdominal pain from a pediatric clinic. Esophagogastroduodenoscopy revealed acute gastritis with duodenogastric reflux and suspicious reflux esophagitis of minimal change, but there was no significant improvement after treatment and as a result she was admitted to the emergency room. She was subsequently diagnosed as Graves` disease because an initial laboratory test at the GI outpatient department revealed thyroid stimulating hormone <0.01 μIU/mL and additional blood tests showed elevated thyroid hormones and positive thyroid stimulating hormone receptor antibody. The vomiting and epigastric pain improved remarkably after treatment with antithyroid drugs. Clinicians should consider the possibility of thyrotoxicosis in patient with unexplained and repeated vomiting. (J Neurogastroenterol Motil 2010;16:428-432)

A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate

( Oya B Sezer ),( Taner Sezer ) 대한소화기기능성질환·운동학회(구 대한소화관운동학회) 2016 Journal of Neurogastroenterology and Motility (JNM Vol.22 No.4

Background/Aims The aim of this study was to compare the efficacy and tolerability of topiramate and propranolol in preventing pediatric cyclic vomiting syndrome. Methods A retrospective medical-record review of patients who underwent prophylaxis after receiving a diagnosis of cyclic vomiting syndrome was performed. Patients who completed at least 12 months of treatment were included in the analysis. Responder rate, and adverseevent rates were also calculated from all patients. Response to treatment was assessed as the total number of vomiting attacks per year. Patients in whom the frequency of vomiting attack reduced greater or equal to 50% were defined as responders, and the remaining patients were classified as nonresponders. Results A total of 38 patients who were treated prophylactically with either topiramate (16 patients) or propranolol (22 patients) were identified. Fifty-nine percent of the patients in the propranolol group and 81% of the patients in the topiramate group reported freedom from attacks. A decrease of more than 50% in attacks per year occurred in 23% of patients in the propranolol group and 13% of patients in the topiramate group. The responder rates were 81% for propranolol group and 94% for topiramate group (P = 0.001). Despite minor adverse effects (drowsiness, nervousness, and dizziness) observed in a few patients, the adverse event rates were not significantly different between the 2 groups (P = 0.240). Conclusions The efficacy of topiramate was superior to propranolol for the prophylaxis of pediatric cyclic vomiting syndrome.